January 12, 2013Open Access
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Key Points
Key points are not available for this paper at this time.
Abstract
Treatment with epratuzumab 2400 mg cd was well tolerated in patients with moderately to severely active SLE, and associated with improvements in disease activity. Phase III studies are ongoing.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
D
Daniel J. Wallace
Cedars-Sinai Medical Center
K
Kenneth Kalunian
University of California System
Michelle Petri
Broad Institute
Journals
Annals of the Rheumatic Diseases
Actions
Institutions
Harvard University
Stanford University
Johns Hopkins University
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...